Compare IDR & LCTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | IDR | LCTX |
|---|---|---|
| Founded | 1996 | 1990 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Precious Metals | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 378.0M | 393.9M |
| IPO Year | N/A | N/A |
| Metric | IDR | LCTX |
|---|---|---|
| Price | $38.02 | $1.72 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 4 |
| Target Price | ★ $17.50 | $4.25 |
| AVG Volume (30 Days) | 425.5K | ★ 2.2M |
| Earning Date | 11-12-2025 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 52.70 | N/A |
| EPS | ★ 0.73 | N/A |
| Revenue | ★ $35,424,313.00 | $10,816,000.00 |
| Revenue This Year | $21.91 | $5.24 |
| Revenue Next Year | $5.47 | $126.78 |
| P/E Ratio | $52.74 | ★ N/A |
| Revenue Growth | ★ 61.35 | 24.05 |
| 52 Week Low | $9.67 | $0.37 |
| 52 Week High | $54.70 | $2.09 |
| Indicator | IDR | LCTX |
|---|---|---|
| Relative Strength Index (RSI) | 55.63 | 49.89 |
| Support Level | $31.22 | $1.57 |
| Resistance Level | $39.88 | $1.76 |
| Average True Range (ATR) | 3.18 | 0.10 |
| MACD | 0.50 | -0.01 |
| Stochastic Oscillator | 68.52 | 46.97 |
Idaho Strategic Resources Inc is a vertically integrated, operating junior mining company. It produces gold at the Golden Chest Mine. In addition to gold and gold production, the company maintains a strategic and domestic presence in the Critical Minerals sector and is focused on advancing its officially recognized Lemhi Pass, Diamond Creek, and Roberts Rare Earth Element projects in central Idaho.
Lineage Cell Therapeutics Inc is a clinical-stage biotechnology company focused on the development and commercialization of novel therapies for the treatment of degenerative diseases. The company's pipeline is based on two platform technologies including cell replacement and cell/drug delivery. Lineage Cell's product candidate is OpRegen, a retinal pigment epithelium transplant therapy for the treatment of dry age-related macular degeneration, OPC1, an oligodendrocyte progenitor cell therapy for acute spinal cord injuries, and VAC2, allogeneic cancer immunotherapy of antigen-presenting dendritic cells for non-small cell lung cancer, ANP1, an allogeneic auditory neuron progenitor cells transplant for hearing loss, and PNC1, an allogeneic photoreceptor cell transplant for vision loss.